Prostate needle biopsy

What we do and what should be improved

Filippo Fraggetta, Pietro Pepe, Giuseppina Improta, Francesco Aragona, Maurizio Colecchia

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Prostate cancer (PCa) is the cancer most frequently diagnosed in older men and the second most frequent for incidence of all tumors. With the widespread use of serum prostate-specific antigen (PSA), the detection rate as well as the incidence of localized tumors has been increasing, thus leading to a drop in PCa-related mortality. However, a corresponding estimated rate of overdiagnosis as high as 50% has been reported, and the adverse side effects related to unnecessary treatments make the overall benefit of PSA mass screening unclear. The lower PSA threshold and extended prostate biopsy protocols have led to a marked increase of small, low-grade tumors that will never threaten a patient's survival. Sextant biopsy technique, extended biopsy protocols (12-18 cores) and saturation prostate schemes are already familiar terms, together with quantitative histology in the pathology departments. This brief review will try to focus on what usually is done and what should be improved in prostate needle biopsy in order to answer many critical points such as the clinical implication of different modalities of prostate biopsy (transrectal, transperineal or even targeted), the use of quantitative histology and the importance of the new molecular findings in addition to conventional histological parameters in the era of the active surveillance protocols.

Original languageEnglish
Pages (from-to)130-138
Number of pages9
JournalAnalytical and Quantitative Cytology and Histology
Volume35
Issue number3
Publication statusPublished - Jun 2013

Fingerprint

Needle Biopsy
Prostate
Prostate-Specific Antigen
Biopsy
Neoplasms
Prostatic Neoplasms
Histology
Mass Screening
Incidence
Pathology
Survival
Mortality
Serum
Therapeutics

Keywords

  • Biopsy
  • Cancer screening
  • Needle
  • Prostate cancer
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Anatomy
  • Histology

Cite this

Prostate needle biopsy : What we do and what should be improved. / Fraggetta, Filippo; Pepe, Pietro; Improta, Giuseppina; Aragona, Francesco; Colecchia, Maurizio.

In: Analytical and Quantitative Cytology and Histology, Vol. 35, No. 3, 06.2013, p. 130-138.

Research output: Contribution to journalArticle

Fraggetta, F, Pepe, P, Improta, G, Aragona, F & Colecchia, M 2013, 'Prostate needle biopsy: What we do and what should be improved', Analytical and Quantitative Cytology and Histology, vol. 35, no. 3, pp. 130-138.
Fraggetta, Filippo ; Pepe, Pietro ; Improta, Giuseppina ; Aragona, Francesco ; Colecchia, Maurizio. / Prostate needle biopsy : What we do and what should be improved. In: Analytical and Quantitative Cytology and Histology. 2013 ; Vol. 35, No. 3. pp. 130-138.
@article{04cac9078af544dd94f571c0f8dc4e61,
title = "Prostate needle biopsy: What we do and what should be improved",
abstract = "Prostate cancer (PCa) is the cancer most frequently diagnosed in older men and the second most frequent for incidence of all tumors. With the widespread use of serum prostate-specific antigen (PSA), the detection rate as well as the incidence of localized tumors has been increasing, thus leading to a drop in PCa-related mortality. However, a corresponding estimated rate of overdiagnosis as high as 50{\%} has been reported, and the adverse side effects related to unnecessary treatments make the overall benefit of PSA mass screening unclear. The lower PSA threshold and extended prostate biopsy protocols have led to a marked increase of small, low-grade tumors that will never threaten a patient's survival. Sextant biopsy technique, extended biopsy protocols (12-18 cores) and saturation prostate schemes are already familiar terms, together with quantitative histology in the pathology departments. This brief review will try to focus on what usually is done and what should be improved in prostate needle biopsy in order to answer many critical points such as the clinical implication of different modalities of prostate biopsy (transrectal, transperineal or even targeted), the use of quantitative histology and the importance of the new molecular findings in addition to conventional histological parameters in the era of the active surveillance protocols.",
keywords = "Biopsy, Cancer screening, Needle, Prostate cancer, Prostate-specific antigen",
author = "Filippo Fraggetta and Pietro Pepe and Giuseppina Improta and Francesco Aragona and Maurizio Colecchia",
year = "2013",
month = "6",
language = "English",
volume = "35",
pages = "130--138",
journal = "Analytical and Quantitative Cytology",
issn = "0884-6812",
publisher = "Science Printers and Publishers Inc.",
number = "3",

}

TY - JOUR

T1 - Prostate needle biopsy

T2 - What we do and what should be improved

AU - Fraggetta, Filippo

AU - Pepe, Pietro

AU - Improta, Giuseppina

AU - Aragona, Francesco

AU - Colecchia, Maurizio

PY - 2013/6

Y1 - 2013/6

N2 - Prostate cancer (PCa) is the cancer most frequently diagnosed in older men and the second most frequent for incidence of all tumors. With the widespread use of serum prostate-specific antigen (PSA), the detection rate as well as the incidence of localized tumors has been increasing, thus leading to a drop in PCa-related mortality. However, a corresponding estimated rate of overdiagnosis as high as 50% has been reported, and the adverse side effects related to unnecessary treatments make the overall benefit of PSA mass screening unclear. The lower PSA threshold and extended prostate biopsy protocols have led to a marked increase of small, low-grade tumors that will never threaten a patient's survival. Sextant biopsy technique, extended biopsy protocols (12-18 cores) and saturation prostate schemes are already familiar terms, together with quantitative histology in the pathology departments. This brief review will try to focus on what usually is done and what should be improved in prostate needle biopsy in order to answer many critical points such as the clinical implication of different modalities of prostate biopsy (transrectal, transperineal or even targeted), the use of quantitative histology and the importance of the new molecular findings in addition to conventional histological parameters in the era of the active surveillance protocols.

AB - Prostate cancer (PCa) is the cancer most frequently diagnosed in older men and the second most frequent for incidence of all tumors. With the widespread use of serum prostate-specific antigen (PSA), the detection rate as well as the incidence of localized tumors has been increasing, thus leading to a drop in PCa-related mortality. However, a corresponding estimated rate of overdiagnosis as high as 50% has been reported, and the adverse side effects related to unnecessary treatments make the overall benefit of PSA mass screening unclear. The lower PSA threshold and extended prostate biopsy protocols have led to a marked increase of small, low-grade tumors that will never threaten a patient's survival. Sextant biopsy technique, extended biopsy protocols (12-18 cores) and saturation prostate schemes are already familiar terms, together with quantitative histology in the pathology departments. This brief review will try to focus on what usually is done and what should be improved in prostate needle biopsy in order to answer many critical points such as the clinical implication of different modalities of prostate biopsy (transrectal, transperineal or even targeted), the use of quantitative histology and the importance of the new molecular findings in addition to conventional histological parameters in the era of the active surveillance protocols.

KW - Biopsy

KW - Cancer screening

KW - Needle

KW - Prostate cancer

KW - Prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=84880027787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880027787&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 130

EP - 138

JO - Analytical and Quantitative Cytology

JF - Analytical and Quantitative Cytology

SN - 0884-6812

IS - 3

ER -